SpringWorks Shares Rise on FDA Approval for Tumor Treatment
November 28 2023 - 6:53AM
Dow Jones News
By Dean Seal
Shares of SpringWorks were higher after the company received
regulatory approval for its treatment of desmoid tumors.
The stock was up 11% at $23.01 in premarket trading. Shares had
fallen 20% year-to-date when the market closed Monday.
The Stamford, Conn.-based biopharmaceutical company said after
the bell on Monday that the U.S. Food and Drug Administration has
approved Ogsiveo for adults with progressing desmoid tumors who
require systemic treatment.
SpringWorks said Ogsiveo was the first FDA-approved therapy for
patients with desmoid tumors.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
November 28, 2023 07:38 ET (12:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
SpringWorks Therapeutics (NASDAQ:SWTX)
Historical Stock Chart
From May 2024 to Jun 2024
SpringWorks Therapeutics (NASDAQ:SWTX)
Historical Stock Chart
From Jun 2023 to Jun 2024
